Ahmedabad, India

Pandurang Zaware

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 2.6

ph-index = 1


Location History:

  • Ahmedabad, IN (2014)
  • Gujarat, IN (2014)

Company Filing History:


Years Active: 2014

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations by Pandurang Zaware

Introduction

Pandurang Zaware is a notable inventor based in Ahmedabad, India. He has made significant contributions to the field of pharmaceuticals, particularly in the development of GPR 119 agonists. With a total of 3 patents to his name, Zaware's work focuses on innovative solutions for treating metabolic disorders.

Latest Patents

Zaware's latest patents include novel GPR 119 agonists that are designed to address obesity and diabetes. The first patent describes these agonists of the general formula (I), including their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts. This invention also covers pharmaceutical compositions containing these compounds, methods for their preparation, and their medical applications. The second patent further elaborates on the GPR 119 agonists, detailing their solvates, enantiomers, stereoisomers, and polymorphs. It emphasizes the processes for preparing these compounds and their potential in treating diabetes and obesity.

Career Highlights

Pandurang Zaware is associated with Cadila Healthcare Limited, a prominent player in the pharmaceutical industry. His work at the company has been instrumental in advancing research and development in the field of metabolic disorders.

Collaborations

Zaware has collaborated with notable colleagues such as Harikishore Pingali and Mukul R Jain. Their combined expertise has contributed to the successful development of innovative pharmaceutical solutions.

Conclusion

Pandurang Zaware's contributions to the field of pharmaceuticals, particularly through his patents on GPR 119 agonists, highlight his role as a significant inventor. His work continues to pave the way for advancements in treating obesity and diabetes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…